Santral Uyku Apne Sendromu
Özet
Santral Uyku Apne Sendromu (SUAS), solunum çabasının olmadığı, üst solunum yolu obstrüksiyonu olmaksızın tekrarlayan apne epizodları ve desatürasyon ile karakterize bir uykuda solunum bozukluğudur. En sık konjestif kalp yetmezliği ve kronik opioid kullanımı nedeniyle gelişen bu sendrom, ICSD-3 sınıflandırmasına göre Cheyne-Stokes solunumu, medikal durumlara bağlı SUAS, yüksek irtifa, ilaç/madde kullanımı, primer (idiyopatik) SUAS, tedavinin açığa çıkardığı SUAS, infant ve prematüre primer SUAS olmak üzere 8 alt gruba ayrılmaktadır. Teşhis sürecinde genellikle saat başına 5 veya daha fazla santral apne saptanması ve bu olayların toplam apnelerin %50'sinden fazlasını oluşturması gibi polisomnografi kriterleri ile uykululuk veya nefes alamama gibi klinik semptomlar esas alınmaktadır. Tedavi yaklaşımları doğrudan altta yatan nedene yönelik olup; agresif ilaç tedavileri, oksijen desteği, CPAP, BPAP ve adaptif servo ventilasyon (ASV) gibi pozitif hava yolu basıncı cihazları ile transvenöz frenik sinir stimülasyonunu içermektedir. Kardiyovasküler hasar ve mortalite riskini azaltmak adına erken tanı ve hastaya özgü tedavi hayati önem taşımaktadır.
Central Sleep Apnea Syndrome (CSAS) is a sleep-related breathing disorder characterized by recurrent apnea episodes without respiratory effort or upper airway obstruction, accompanied by desaturation. Most commonly caused by congestive heart failure and chronic opioid use, this syndrome is divided into 8 subgroups according to the ICSD-3 classification: CSAS with Cheyne-Stokes respiration, CSAS due to medical conditions, high altitude, drug/substance use, primary (idiopathic) CSAS, treatment-emergent CSAS, and primary CSAS of infants and prematures. Diagnosis is fundamentally based on clinical symptoms like sleepiness or waking up gasping, alongside polysomnography criteria typically requiring 5 or more central apneas per hour, which must constitute more than 50% of the total apnea events. Treatment strategies directly target the underlying cause, encompassing aggressive medical management, oxygen support, positive airway pressure devices such as CPAP, BPAP, and adaptive servo-ventilation (ASV), as well as transvenous phrenic nerve stimulation. Early diagnosis and patient-specific tailored treatment remain vital to significantly reduce the risk of cardiovascular damage, morbidity, and mortality.
Referanslar
Guilleminault C, van den Hoed J, Mitler M: Clinical overview of the sleep apnea syndromes. In: Guilleminault C, Dement WC, ed Sleep Apnea Syndromes. New York, Alan R Liss, 1978: 1-11
Lanfranchi PA, Braghiroli A, Bosimini E: Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation.1999 mar 23;99(11):1435-40.doi:10.1161/01.cir99.11.143
Amerikan Uyku Tıbbı Akademisi Uluslararası Uyku Bozuklukları Sınıflandırması . Amerikan Uyku Tıbbı Akademisi, 3. baskı.Darien, IL, ABD:2014.
Bradley TD, Floras JS Sleep apnea and heart failure: Part II: central sleep apnea.Circulation. 2003 8 April; 107(13):1822-6. doi: 10.1161/01.CIR.0000061758.05044.64.
New Classification of Sleep Disorders (ICSD-3) What Has Changed in Sleep Breathing Disorders? Güncel Göğüs Hastalıkları Serisi 2014; 2 (2): 139-151.
Naughton MT, Kee K: Sleep apnoea in heart failure: To treat or not to treat?. Solunum bilim. 2017 february; 22(2):217-229. doi: 10.1111/resp.12964
Lanfranchi PA, Braghiroli A, Bosimini E: Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation.1999 mar 23;99(11):1435-40.
44. Javaheri S, Parker TJ, Wexler L, Liming JD: Effect of theophylline on sleep-disordered breathing in heart failure. Solunum bilim. 2017 february; 22(2):217-229. doi: 10.1111/resp.12964
Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study. Am J Respir Crit Care Med. 2006 Jan 15;173(2):234-7. doi: 10.1164/rccm.200507-1035OC.
Fontana M, Emdin M, Giannoni A, Iudice: Effect of acetazolamide on chemosensitivity, Cheyne-Stokes respiration, and response to effort in patients with heart failure. Am J Cardiol. 2011 1;107(11): 1675-80. doi: 10.1016/j.amjcard.2011.01.060
Bordier P. Sleep apnoea in patients with heart failure: part II: therapy.Arch cardiovasc dis.2009 oct;102(10)711-20. Doi: 10i1016/j.acvd.2009.06.005.
Beyaz Sol, Bradley TD. Role of nocturnal rostral fluid shift in the pathogenesis of obstructive and central sleep apnoea. J Physiol. 2013 Mar 1;591(5):1179-93.doi:10.1113/jphsiol.2012.245159
Billings ME, Johnson DA, Simonelli G: Neighborhood Walking Environment and Activity Level Are Associated With OSA: The Multi-Ethnic Study of Atherosclerosis. Chest. 2016 Nov;150(5):1042-1049. doi:10.16/j.chest.2016.06.012
Bradley TD, Logan AG, Kimoff RJ: CANPAP Investigators. Continuous positive airway pressure sentral apnea and heart failure.N engel J Med: 2005;353;2025-2033. Doi:10.1056/NEJMoa05100
Arzt M, Floras JS, Logan AG: CANPAP Investigators. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). 2007 Jun 26;115(25):3173-80.
Teschler H, Döhring J, Wang YM: Adaptive pressure support servo-ventilation: a novel treatment for Cheyne-Stokes respiration in heart failure. J Respir Crit Care Med. 2001; 164 :614-619. Doi:10.1164/ajrccm.164.4.9908114.
Javaheri S, Brown LK, Randerath WJ. Positive airway pressure therapy with adaptive servoventilation: part 1: operational algorithms.Chest. 2014; 146 :514–523. doi: 10.1378/chest.13-1776.
Arzt M, Wensel R, Montalvan S: Effects of dynamic bilevel positive airway pressure support on central sleep apnea in men with heart failure.Chest. 2008; 134 :61-66. doi: 10.1378/chest.07-1620.
D'Elia E, Vanoli E, La Rovere MT: Adaptive servo ventilation reduces central sleep apnea in chronic heart failure patients: beneficial effects on autonomic modulation of heart rate.J Cardiovasc Med (Hagerstown) 2013; 14 :296–300. doi: 10.2459/JCM.0b013e32835364b2
Oldenburg O, Schmidt A, Lamp B: Horstkotte Adaptive servoventilation improves cardiac function in patients with chronic heart failure and Cheyne-Stokes respiration Eur J Heart Fail 2008 Jun;10(6):581-6. doi:10.1016/j.ejheart.2008.04.007
Hastings PC, Vazir A, Meadows GE: Adaptive servo-ventilation in heart failure patients with sleep apnea: a real world study. Int J Cardiol. 2010; 139 :17–24. doi: 10.1016/j.ijcard.2008.08.022.
Cowie MR, Woehrle H, Wegscheider K: Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. N Engl J Med. 2015; 373 :1095–1105.
Javaheri S, Brown LK, Randerath W: SERVE-HF: CSERVE-HF: More Questions Than Answers. Chest. 2016; 149 :900–904. doi: 10.1016/j.chest.2015.12.021.
Bradley TD, Floras JS: ADVENT-HF The SERVE-HF Trial. Can Respir J. 2015; 22 :313. doi: 10.1155/2015/751615
Costanzo MR, Ponikowski P, Javaheri S, remedé System Pivotal Trial Study Group. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. Lancet. 2016; 388 :974-982. doi: 10.1016/S0140-6736(16)30961
Uykuder 2021 Uyku Bozuklukları Kongresi 12. Uyku Bozuklukları Kursu 30 Nisan /1-2 Mayıs 2021 - Dijital Platform
Barcroft J.Kanın solunum fonksiyonu, bölüm 2 . Yüksek irtifadan dersler . Cambridge : Cambridge University Press , 1925 .
Some experiences of mountain sickness in the ANDES . Journal of Tropical Medicine and Hygiene, 1913 ; 16 : 313 – 320.
Anholm JD ,Powles AC ,Downey R ,Houston CS :Everest Operasyonu. Operation Everest II: arterial oxygen saturation and sleep at extreme simulated altitude. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):817-26.doi: 10.1164/ajrccm/145.4_Pt_1.817.
F Goldenberg , JP Richalet , I Onnen . Sleep apneas and high altitude newcomersUyku apneas. Int J Spor Med 1992 ; 13 : S34 - S36
Fischer R, Lang S, Leitl M:Theophylline and acetazolamide reduce sleep-disordered breathing at high altitude. Eur Respir J 2004;23:47-52. doi: 10.1183/09031936.03.00113102.
4. Nickol A, Leverment J, Richards P:Cleland J, et al. Temazepam at high altitude reduces periodic breathing without impairing next-day performance: a randomized cross-over double-blind study. J Sleep Res 2006;15:445-54. doi: 10.1111/j.1365-2869.2006.00558.x.
Beaumont M, Batejat D, Coste O: Clère JM, et al. Effects of Zolpidem and Zaleplon on sleep, respiratory patterns and performance at a simulated altitude of 4000 m. Neuropsychobiology 2004;49:154-62. doi: 10.1159/000076723.
Aurora RN, Chowdhuri S, Ramar K: Lamm CI, et al. The treatment of central sleep apnea syndromes in adults: practice parameters with an evidencebased literature review and meta-analyses. Sleep 2012;35:17-40. doi: 10.5665/sleep.1580
Han B, Compton WM, Blanco C: Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health.Ann Intern Med:2017;167:293-301. doi:10.7326/M17-0865.
Seth P, Scholl L, Rudd RA:Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants - United States,2015-2016MMWR Morb Mortal Wkly Rep. Doi:10.15585/mmwr.mm6712a1.
Bailey PL, Lu JK, Pace NL, et al. Effects of intrathecal morphine on the ventilatory response to hypoxia. N Engl J Med. 2000;343:1228–1234. doi: 10.1056/NEJM200010263431705
Amerikan Uyku Tıbbı Akademisi. Uluslararası Uyku Bozuklukları Sınıflandırması, Üçüncü Baskı: Teşhis ve Kodlama Kılavuzu. 2014.Amerikan Uyku Tıbbı Akademisi;
Javaheri S, Dempsey JA. Central sleep apnea. Comp. Phsiyol. 2013;3;141-163i doi: 10.1002/chpt.c.110057
Correa D, Farney RJ, Chung F: Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations. Anesth Analg. 2015 Jun;120(6):1273-85. doi: 10.1213/ANE.0000000000000672
Lalley PM. Opiate slowing of feline respiratory rhythm and effects on putative medullary phase-regulating neurons. J Physiol Regul Integr Comp Physiol. 2006;290: R1387–R1396. doi: 10.1152/ajpregu.00530.2005
Aurora RN, Chowdhuri S, Ramar K, et al: The treatment of central sleep apnea syndromes im adults practice parameters with anevidence-based literatüre review and meta –analyses. Sleep. 2012;3517-40
Rosen IM, Aurora RN, Kirsch DB, ve diğerleri; Chronic Opioid Therapy and Sleep: An American Academy of Sleep Medicine Position Statement. J Clin Sleep Med. 2019;15:1671. Doi:10.5664/jcsm.8062
Walker JM, Farney RJ, Rhondeau SM, et al. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing.J Clin Uyku Med. 2007;3:455–461.
Naughton MT. Cheyne-Stokes respiration: friend or foe? Thorax. 2012;67:357–360. doi: 10.1136/thoraxjnl-2011-200927
Wang D, Rowsell L, Yee BJ. Positive airway pressure treatment for opioid-related central sleep apnea, where are we now? Sleep and breathingvolume. 2014;18:229–231.
Farney RJ, Walker JM, Cloward TV: Sleep-disordered breathing associated with long-term opioid therapy. Chest. 2003;123: 632–639. doi: 10.1378/chest.123.2.632
Chowdhuri S, Ghabsha A, Sinha P: Treatment of central sleep apnea in U.S. veterans. J Clin sleep Med. 2012;8: 555-563. doi: 10.5664/jcsm.2156
Smith JC, Abdala AP, Koizumi H: Memeli beyin sapı solunum ağının mekansal ve fonksiyonel mimarisi: üç salınım mekanizmasının hiyerarşisi. Spatial and functional architecture of the mammalian brain stem respiratory network: a hierarchy of three oscillatory mechanisms. J Nörofizyol. 2007;98: 3370–3387. doi: 10.1152/jn.00985.2007.
Schwarzer A, Aichinger-Hinterhofer M, Maier C: Sleep-disordered breathing decreases after opioid withdrawal: results of a prospective controlled trial.pain.2015;156:2167-2174. doi: 10.1097/j.pain.0000000000000279.
Wang D, Lintzeris N, Leung S: Reversal of central sleep apnoea with change from methadone to buprenorphine-naloxone: a case report. Eur Respir J. 2015;46: 102–1205. Doi: 10.1183/09031936.00051315
Javaheri S, Harris N, Howard J: Adaptive servoventilation for treatment of opioid-associated central sleep apnea. J Clin sleep Med. 2014;10: 637–643. doi: 10.5664/jcsm.3788
Javaheri S, Malik A, Smith J: Adaptive pressure support servoventilation: a novel treatment for sleep apnea associated with use of opioids. J Clin sleep Med. 2008;4:305–310.
Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. N Engl J Med. 2015;373:1095–1105. doi: 10.1056/NEJMoa1506459
Javaheri S, Barbe F, Campos-Rodriguez F, et al. Sleep Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences. J Am Coll Cardiol. 2017;69:841-858.doi:10.1016/j.jacc.2016.11.069.
DeBacker WA, Verbraecken J, Willemen M: Central apnea index decreases after prolonged treatment with acetazolamide. J Respir Crit Care Med. 1995 Ocak; 151(1):87-91. doi: 10.1164/ajrccm.151.1.7812578.
Roehrs T, Conway W, Wittig R: Sleep-wake complaints in patients with sleep-related respiratory disturbances.Rev Respir Dis. 1985 september; 132(3):520-3. doi:10.1164/arrd.1985.132.3.520
Aurora RN, Chowdhuri S, Ramar K: The treatment of central sleep apnea syndromes in adults: practice parameters with an evidence-based literature review and meta-analyses. Sleep 2012; 35: 17-40.
Bradley TD, McNicholas WT, Rutherford R: Clinical and physiologic heterogeneity of the central sleep apnea syndrome.Rev Respir Dis. 1986 Agu; 134(2):217-21. doi: 10.1164/arrd.1986.134.2.217.
Bonnet M, Dexter J, Arand D. The effect of triazolam on arousal and respiration in central sleep apnea patients. Sleep 1990; 13: 31-41.
Shahrokh Javaheri, MD Scott McKane, MS. Transvenous phrenic nerve stimulation to treat idiopathic central sleep apnea: Journal of Clinical Sleep MedicineVol. 16, No. 12; :December 15, 2020
Nigam G, Pathak C, Riaz M Ann. A systematic review on prevalence and risk factors associated with treatment- emergent central sleep apnea. Ann Thorac Med. 2016 Jul-Sep; 11(3): 202–210. doi:10.4103/1817-1737.185761.
Westhoff M, Arzt M, Litterst P. Prevalence and treatment of central sleep apnoea emerging after initiation of continuous positive airway pressure in patients with obstructive sleep apnoea without evidence of heart failure. Seep and breathing 16, 71-78(2012)
Khan MT, Franco RA Complex sleep apnea syndrome Sleep dis. 2014; 2014:798487. Doi:10.1155/2014/798487
